Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers

Clin Pharmacokinet. 2016 Aug;55(8):1003-14. doi: 10.1007/s40262-016-0373-8.

Abstract

Background and aims: The three direct-acting antiviral regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir (3D regimen) is approved for treatment of hepatitis C virus (HCV) genotype 1 infection. Drug-drug interaction (DDI) studies of the 3D regimen and commonly used medications were conducted in healthy volunteers to provide information on coadministering these medications with or without dose adjustments.

Methods: Three phase I studies evaluated DDIs between the 3D regimen (ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily + dasabuvir 250 mg twice daily) and hydrocodone bitartrate/acetaminophen (5/300 mg), metformin hydrochloride (500 mg), diazepam (2 mg), cyclobenzaprine hydrochloride (5 mg), carisoprodol (250 mg), or sulfamethoxazole/trimethoprim (SMZ/TMP) (800/160 mg twice daily), all administered orally. DDI magnitude was determined using geometric mean ratios and 90 % confidence intervals for the maximum plasma concentration (C max) and area under the plasma concentration-time curve (AUC).

Results: Changes in exposures (C max and AUC geometric mean ratios) of acetaminophen, metformin, sulfamethoxazole, trimethoprim, and diazepam were ≤25 % upon coadministration with the 3D regimen. The C max and AUC of nordiazepam, an active metabolite of diazepam, increased by 10 % and decreased by 44 %, respectively. Exposures of cyclobenzaprine and carisoprodol decreased by ≤40 and ≤46 %, respectively, whereas exposures of hydrocodone increased up to 90 %. Ombitasvir, paritaprevir, ritonavir, and dasabuvir exposures changed by ≤25 %, except for a 37 % decrease in paritaprevir C max with metformin and a 33 % increase in dasabuvir AUC with SMZ/TMP.

Conclusions: Acetaminophen, metformin, sulfamethoxazole, and trimethoprim can be coadministered with the 3D regimen without dose adjustment. Higher doses may be needed for diazepam, cyclobenzaprine, and carisoprodol based on clinical monitoring. A 50 % lower dose and/or clinical monitoring should be considered for hydrocodone. No dose adjustment is necessary for the 3D regimen.

Publication types

  • Clinical Trial, Phase I

MeSH terms

  • 2-Naphthylamine
  • Adolescent
  • Adult
  • Anilides / administration & dosage*
  • Anilides / pharmacokinetics
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / pharmacokinetics
  • Carbamates / administration & dosage*
  • Carbamates / pharmacokinetics
  • Cyclopropanes
  • Drug Interactions
  • Drug Therapy, Combination / methods*
  • Female
  • Healthy Volunteers
  • Hepacivirus / drug effects
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Lactams, Macrocyclic
  • Macrocyclic Compounds / administration & dosage*
  • Macrocyclic Compounds / pharmacokinetics
  • Male
  • Middle Aged
  • Pharmacokinetics
  • Proline / analogs & derivatives
  • Ritonavir / administration & dosage*
  • Ritonavir / pharmacokinetics
  • Sulfonamides / administration & dosage*
  • Sulfonamides / pharmacokinetics
  • Uracil / administration & dosage
  • Uracil / analogs & derivatives*
  • Uracil / pharmacokinetics
  • Valine
  • Young Adult

Substances

  • Anilides
  • Antiviral Agents
  • Carbamates
  • Cyclopropanes
  • Lactams, Macrocyclic
  • Macrocyclic Compounds
  • Sulfonamides
  • ombitasvir
  • Uracil
  • Proline
  • 2-Naphthylamine
  • dasabuvir
  • Valine
  • Ritonavir
  • paritaprevir